• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Clin Invest . Myocardial injury in patients with SARS-CoV-2 pneumonia: pivotal role of inflammation in COVID-19

tetano

Editor, Senior Moderator
Eur J Clin Invest


. 2021 Oct 27;e13703.
doi: 10.1111/eci.13703. Online ahead of print.
Myocardial injury in patients with SARS-CoV-2 pneumonia: pivotal role of inflammation in COVID-19


Francesco Melillo[SUP] 1 [/SUP], Antonio Napolano[SUP] 1 [/SUP], Marco Loffi[SUP] 2 [/SUP], Valentina Regazzoni[SUP] 2 [/SUP], Antonio Boccellino[SUP] 1 [/SUP], Gian Battista Danzi[SUP] 2 [/SUP], Alberto Maria Cappelletti[SUP] 3 [/SUP], Patrizia Rovere-Querini[SUP] 4 5 [/SUP], Giovanni Landoni[SUP] 5 6 [/SUP], Giacomo Ingallina[SUP] 1 [/SUP], Stefano Stella[SUP] 1 [/SUP], Francesco Ancona[SUP] 1 [/SUP], Lorenzo Dagna[SUP] 5 7 [/SUP], Paolo Scarpellini[SUP] 8 [/SUP], Marco Ripa[SUP] 8 [/SUP], Antonella Castagna[SUP] 5 8 [/SUP], Moreno Tresoldi[SUP] 9 [/SUP], Alberto Zangrillo[SUP] 5 6 [/SUP], Fabio Ciceri[SUP] 5 10 [/SUP], Eustachio Agricola[SUP] 1 5 [/SUP]



Affiliations

Abstract

Aims: Infection by SARS-CoV-2 may result in a systemic disease and a proportion of patients ranging 15-44% experienced cardiac injury (CI) diagnosed by abnormal troponin levels. The aim of the present study was to analyse the clinical characteristics of a large series of hospitalized patients for COVID-19 in order to identify predisposing and/or protective factors of CI and the outcome.
Methods and results: This is an observational, retrospective study on patients hospitalized in two Italian centres (San Raffaele Hospital and Cremona Hospital) for COVID-19 and at least one high-sensitivity cardiac troponin (hs-cTnt) measurement during hospitalization. CI was defined if at least one hs-cTnt value was above the 99th percentile. The primary end-point was the occurrence of CI during hospitalization. We included 750 patients (median age 67, IQR 56-77 years, 69% males), of whom 46.9% had history of hypertension, 14.7% of chronic coronary disease and 22.3% of chronic kidney disease (CKD). Abnormal troponin levels (median troponin 74, IQR 34-147 ng/l) were detected in 390 patients (52%) during the hospitalization. At multivariable analysis age, CKD, cancer, C-reactive protein (CRP) levels were independently associated with CI. Independent predictors of very high troponin levels were chronic kidney disease and CRP levels. Patients with CI showed higher rate of all-cause mortality (40.0% vs 9.1%, p=0.001) compared to those without CI.
Conclusion: This large, multicenter Italian study confirmed the high prevalence of CI and its prognostic role in hospitalized patients with COVID-19, highlighting the leading role of systemic inflammation for the occurrence of CI.

Keywords: COVID-19; SARS-coronavirus-2; cardiac complications; myocardial injury; troponin.
 
Back
Top Bottom